摘要 ： 基于此，仪器信息网整理汇总了食品领域15家全国重点实验室的仪器设备明细，以供读者参考。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 据统计，目前食品领域已有1 5个全国重点实验室获批或完成重组。实验室是科学研究的基础， 助力科研人员破解科学难题、攻克关键技术、推动成果转化，而科学仪器正是实验室开展科研 工作的重要工具。 基于此，仪器信息网整理汇总了食品领域全国重点实验室的仪器设备明细， 以供读者参考。 整体而言，实验室普遍配备了大量高端精密仪器，如高分辨液相色谱质谱联用仪、激光共聚焦 显微镜、核磁共振系统等，这些设备多以进口品牌为主，且单台价值高昂，许多实验室的设备 总资产超过亿元。 不同实验室的配置存在差异。 一方面，部分已运行成熟的实验室（如资源昆虫、木本油料实验 室）拥有价值数亿元的仪器平台，体系完备；另一方面，一些新近组建或重组的实验室（如肉 品质量控制、生物反应器工程实验室）正处于建设期，未来仪器采购需求预计较为旺盛。 从研 究方向看，仪器配置也各有侧重：成分分析与安全检测方向依赖各类色谱-质谱联用仪；细胞与 微生 ...

Company Overview - Chuangguang Medical's closing price on June 9 was 20.84 yuan, an increase of 4.67%, with a latest price-to-book ratio of 8.15 and a total market capitalization of 1.789 billion yuan [1] - The company specializes in the research, production, and sales of medical imaging superconducting MRI equipment and core hardware, as well as special magnets for scientific research [1] - Major products include nuclear magnetic resonance systems, superconducting magnets, RF detectors, gradient coils, RF amplifiers, and gradient amplifiers [1] - The company is recognized as a high-tech enterprise focusing on independent research and development, having received several accolades including "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" [1] Patent and Intellectual Property - As of December 31, 2024, the company holds a total of 91 valid patents, including 21 invention patents, 60 utility model patents, and 8 design patents [1] - The company has also obtained 5 software copyrights and has 30 domestic patent applications and 6 PCT patent applications under review [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 25.0744 million yuan, representing a year-on-year increase of 20.21% [1] - The net profit for the same period was -8.5827 million yuan, showing a year-on-year change of 5.22% [1] - The sales gross margin was reported at 30.84% [1] Industry Comparison - Chuangguang Medical's PE (TTM) is -29.61, while the industry average is 50.64, indicating a significant disparity [2] - The company's market capitalization stands at 1.789 billion yuan, compared to the industry median of 50.67 billion yuan [2]

Core Viewpoint - The article highlights the financial performance and market position of Chenguang Medical, emphasizing its focus on R&D in the medical imaging sector and its recent financial results [1]. Company Overview - Chenguang Medical specializes in the research, production, and sales of superconducting MRI equipment and core hardware, as well as specialized magnets for scientific research [1]. - The company has been recognized as a high-tech enterprise, receiving various accolades such as "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" in Shanghai [1]. Financial Performance - As of the first quarter of 2025, Chenguang Medical reported a revenue of 25.07 million yuan, representing a year-on-year increase of 20.21% [1]. - The net profit for the same period was -8.58 million yuan, showing a year-on-year change of 5.22% [1]. - The company's gross profit margin stood at 30.84% [1]. Market Position - Chenguang Medical's latest closing price was 20.7 yuan, with a market capitalization of 1.777 billion yuan and a price-to-book ratio of 8.10 [1]. - The company holds 91 valid patents, including 21 invention patents and 60 utility model patents, indicating a strong emphasis on innovation [1]. Industry Comparison - Chenguang Medical's price-to-earnings (P/E) ratio (TTM) is -29.41, which is significantly lower than the industry average of 50.80 [2]. - The industry median P/E ratio is 36.71, suggesting that Chenguang Medical is currently undervalued compared to its peers [2].